Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus HISTAFED.
AZELASTINE HYDROCHLORIDE vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination